{"id":"exp_1702400000000","title":"Efficient Transformer Variants for Edge Deployment","bit":"Transformer models are too large and slow for edge devices","flip":"Develop compressed transformer variants using knowledge distillation and quantization","hypothesis":"A 10x smaller transformer can maintain 95% of performance through careful distillation and 8-bit quantization","evaluationPlan":"1. Baseline: Measure BERT-base performance on GLUE benchmark\n2. Apply knowledge distillation with temperature scaling\n3. Implement 8-bit quantization with QAT\n4. Measure: model size, inference latency, GLUE scores\n5. Statistical tests: paired t-tests on each GLUE task","expectedOutcomes":"- Model size: 440MB → 44MB\n- Inference time: 50ms → 5ms\n- GLUE score: 82.5 → 78.4 (95% retention)","risksAndMitigation":"Risk: Catastrophic performance drop on specific tasks\nMitigation: Task-specific fine-tuning after compression","relatedWork":["DistilBERT (Sanh et al., 2019)","TinyBERT (Jiao et al., 2020)","Q8BERT (Zafrir et al., 2019)"],"timeline":"4 weeks: 1 week setup, 2 weeks experiments, 1 week analysis","createdDate":"2024-01-10T09:00:00Z"}
{"id":"exp_internal_satiety_regulation","title":"Internal Satiety Regulation Mechanism Test","bit":"Gila monsters survive through energy storage alone","flip":"Gila monsters use endogenous bioactive compounds for internal appetite/metabolic regulation during fasting periods","hypothesis":"Endogenous exendin-4 and related compounds are released systemically during fasting to suppress appetite and regulate glucose metabolism in Gila monsters themselves","evaluationPlan":"1. Longitudinal monitoring of captive Gila monsters during controlled fasting cycles (0, 30, 60, 120 days)\n2. Blood sampling for bioactive compound quantification (plasma exendin-4 via ELISA)\n3. Behavioral feeding assays following fasting periods (feeding latency, meal size)\n4. GLP-1 receptor antagonist trials to test causal mechanism\n5. Statistical analysis: correlation between plasma exendin-4 and fasting duration (p<0.05), effect size Cohen's d ≥0.8","expectedOutcomes":"- Plasma exendin-4 levels increase during extended fasting\n- GLP-1R antagonist treatment increases food intake ≥50% post-fasting\n- Significant correlation between endogenous compound levels and feeding suppression","implications":"Would validate that venom compounds serve dual functions (external predation + internal regulation), revolutionizing understanding of venom evolution and opening new therapeutic discovery pathways","relatedWork":["Christel & DeNardo 2005 - Exendin-4 mechanical release","Yap & Misuan 2018 - Exendin-4 therapeutic applications","McCue 2007 - Snake starvation mechanisms"],"vectors":"Primary risk: Individual variation may obscure population effects. Mitigation: repeated measures design with n≥12 individuals, within-subject controls","priority":"high","status":"proposed","notes":"Core bit flip experiment - could invalidate entire research direction if proven wrong","createdDate":"2025-08-09T20:42:00Z"}
{"id":"exp_compound_discovery","title":"Comprehensive Bioactive Compound Discovery","bit":"Exendin-4 is the primary bioactive compound in Gila monster saliva","flip":"Gila monster saliva contains multiple undiscovered satiety-promoting compounds beyond exendin-4 that work synergistically","hypothesis":"Gila monster saliva contains ≥5 distinct bioactive compounds that demonstrate satiety-promoting effects when tested individually and synergistically","evaluationPlan":"1. High-resolution chromatographic fractionation of fresh Gila monster saliva (≥50 fractions)\n2. Mass spectrometry identification of novel peptide sequences\n3. Synthetic peptide generation for bioactivity confirmation\n4. Multi-parametric bioassay screening using rodent models (food intake, GLP-1R activation, glucose tolerance)\n5. Success metrics: ≥3 compounds with IC50 < 10 μM for food intake suppression, combined effects >50% greater than additive","expectedOutcomes":"- Identification of 3-7 novel bioactive peptides\n- ≥3 compounds show significant satiety effects (>30% food intake reduction)\n- Synergistic interactions between multiple compounds\n- Novel sequences with <50% homology to known peptides","implications":"Would establish Gila monster saliva as a treasure trove of therapeutic compounds, supporting natural product discovery over synthetic design approaches","relatedWork":["Sanggaard et al. 2015 - Gila monster venom proteome","Koludarov et al. 2017 - Multifunctional venom evolution","Szayna et al. 2000 - Exendin-4 bioactivity"],"vectors":"Primary risk: Saliva degradation affecting bioactivity. Mitigation: flash-frozen collection, protease inhibitors, <6h processing","priority":"high","status":"proposed","notes":"Discovery phase experiment - fundamental to identifying new therapeutic targets","createdDate":"2025-08-09T20:42:00Z"}
{"id":"exp_comparative_adaptation","title":"Comparative Metabolic Adaptation Analysis","bit":"Desert reptile fasting strategies are broadly similar across species","flip":"Gila monster's integrated bioactive compound-metabolic regulation system represents a unique evolutionary solution not found in other desert reptiles","hypothesis":"Gila monsters possess uniquely complex salivary bioactive compound profiles and superior metabolic flexibility compared to other desert-adapted reptiles","evaluationPlan":"1. Controlled fasting trials with phylogenetically diverse desert reptile species (Gila monster, bearded dragon, chuckwalla, desert iguana)\n2. Comparative proteomics of salivary secretions across species\n3. Cross-species bioactivity testing of salivary compounds\n4. Metabolic profiling during fasting progression (indirect calorimetry)\n5. Success metrics: Gila monster fasting survival ≥2x longer, salivary complexity ≥200% higher, ≥5 unique bioactive compounds","expectedOutcomes":"- Gila monsters show superior fasting capacity vs. related species\n- Unique compound classes present only in Heloderma lineage\n- Correlation between compound complexity and fasting ability","implications":"Would establish Gila monsters as uniquely adapted, justifying focus on this species for therapeutic discovery and validating evolutionary approach to drug discovery","relatedWork":["Hughes 2022 - Gila monster body size variation","Ruxton 2024 - Optimal digestive strategy in snakes","Koludarov et al. 2014 - Conserved venom profiles"],"vectors":"Primary risk: Phylogenetic confounding. Mitigation: include both closely related (Helodermatidae) and distant (Iguanidae) species","priority":"medium","status":"proposed","notes":"Validates uniqueness of Gila monster strategy through comparative approach","createdDate":"2025-08-09T20:42:00Z"}
{"id":"exp_synergy_analysis","title":"Multi-Compound Synergy Mechanism Analysis","bit":"Single-target drugs are superior to multi-compound natural products","flip":"Natural multi-compound systems provide superior therapeutic outcomes through integrated pathway modulation rather than single-target approaches","hypothesis":"Combinations of Gila monster bioactive compounds demonstrate synergistic effects on satiety and glucose regulation that exceed additive individual compound effects","evaluationPlan":"1. Systematic combination matrix testing using factorial design (all pairwise and 3-way combinations)\n2. Pathway-specific reporter assays for mechanism identification\n3. In vivo efficacy testing in diabetic/obese rodent models\n4. Mathematical modeling of synergy using Loewe additivity and Bliss independence\n5. Success metrics: Combination Index <0.8 for synergistic pairs, therapeutic index improvement ≥3-fold","expectedOutcomes":"- ≥3 compound pairs show synergistic interactions (CI<0.8)\n- Multi-compound treatments effective at ≥5x lower individual concentrations\n- Broader pathway coverage with reduced side effects","implications":"Would validate multi-target natural product approach over reductionist single-target drug design, potentially revolutionizing pharmaceutical development strategy","relatedWork":["Eng 2004 - Exenatide pharmacology multi-mechanisms","Yap & Misuan 2018 - Natural vs synthetic exendin-4","Koludarov et al. 2017 - Multifunctional venom proteins"],"vectors":"Primary risk: Complex pharmacokinetic interactions confounding results. Mitigation: PK/PD modeling, time-course analysis","priority":"medium","status":"proposed","notes":"Tests fundamental assumption about multi-target vs single-target therapeutics","createdDate":"2025-08-09T20:42:00Z"}
{"id":"exp_trade_off_analysis","title":"Evolutionary Trade-off Cost Analysis","bit":"Gila monster fasting adaptation has no significant evolutionary costs","flip":"Extended fasting adaptation involves significant reproductive, immune, or developmental costs that represent fundamental constraints on the survival strategy","hypothesis":"Gila monster fasting adaptations involve measurable costs in reproductive success, immune function, or developmental processes that constrain the strategy's broader applicability","evaluationPlan":"1. Multi-generational breeding colony with controlled fasting regimens\n2. Immune challenge experiments with standardized pathogens\n3. Longitudinal growth tracking with morphometric analysis\n4. Stress biomarker profiling across fasting cycles\n5. Success metrics: significant (p<0.05) reproductive/immune costs with effect size d≥0.5, trade-offs in ≥2 physiological systems","expectedOutcomes":"- Reproductive costs: 20-40% reduction in clutch size following extended fasting\n- Immune suppression: increased pathogen susceptibility\n- Developmental delays: slower juvenile growth rates during fasting cycles","implications":"Would identify fundamental constraints on extreme fasting adaptation, informing realistic therapeutic applications and understanding ecological trade-offs","relatedWork":["Hughes 2022 - Geographic body size patterns","McCue 2007 - Starvation survival mechanisms","General life history trade-off theory"],"vectors":"Primary risk: Laboratory conditions may not reflect natural trade-offs. Mitigation: semi-natural outdoor enclosures, naturalistic breeding","priority":"medium","status":"proposed","notes":"Critical for understanding limitations and ecological context of fasting adaptations","createdDate":"2025-08-09T20:42:00Z"}